Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06257485 · ClinicalTrials.gov registry record
Bronx Transthyretin Amyloid Cardiomyopathy Database
A clinical trial of Transthyretin Cardiac Amyloidosis and Transthyretin Amyloid Cardiomyopathy, sponsored by Montefiore Medical Center.
- Active
- Registry status
- 476
- Enrollment target
- 1
- Study location
NCT06257485: Active study of Transthyretin Cardiac Amyloidosis and Transthyretin Amyloid Cardiomyopathy, sponsored by Montefiore Medical Center.
NCT06257485 is a study of Transthyretin Cardiac Amyloidosis and Transthyretin Amyloid Cardiomyopathy that is active but no longer recruiting, run by Montefiore Medical Center. The registered enrollment target is 476 participants, roughly in line with the 517-participant average among 4 other Transthyretin Cardiac Amyloidosis trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06257485, a study of Transthyretin Cardiac Amyloidosis and Transthyretin Amyloid Cardiomyopathy, is active but no longer recruiting, sponsored by Montefiore Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 476 participants
- Enrollment target
- 1
- Study location
Study Summary
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PYP) Single Photon Emission Computed Tomography (SPECT) between 2014 and 2023 at Montefiore-Einstein in the Bronx. The patient population is racially and ethnically diverse and with a high proportion of females. Demographic, clinical (e.g. comorbidities), laboratory, echocardiographic, hospitalization, and mortality data were collected for each patient.
Primary Outcome
The number of patients who underwent a PYP SPECT scan diagnostic of ATTR-CM will be assessed and reported
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 99mTc-pyrophosphate Single Photon Emission Computed Tomography
Study Locations (1)
New York
- Montefiore Health System - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 476 participants |
| Start Date | 2023-09-23 |
| Est. Completion | 2026-12 |
What the registry record for NCT06257485 still lists
NCT06257485 is an observational study that tracks outcomes without assigning an intervention. The registered 476 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 517-participant average among 4 other Transthyretin Cardiac Amyloidosis trials with a reported enrollment target.
The record links to 2 conditions, with Transthyretin Cardiac Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which 99mTc-pyrophosphate Single Photon Emission Computed Tomography is the first listed.
NCT06257485 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06257485 about?
NCT06257485 is a clinical study titled "Bronx Transthyretin Amyloid Cardiomyopathy Database". Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PY...
What is the current status of trial NCT06257485?
This trial is currently active not recruiting. The enrollment target is 476 participants. The study started on 2023-09-23. Estimated completion is 2026-12.
What conditions does trial NCT06257485 study?
This clinical trial studies the following conditions: Transthyretin Cardiac Amyloidosis, Transthyretin Amyloid Cardiomyopathy.
What interventions are being tested in trial NCT06257485?
The interventions under investigation include: 99mTc-pyrophosphate Single Photon Emission Computed Tomography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06257485?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06257485 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Cardiac Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation
RECRUITING · Phase 4
-
Exercise Training in Transthyretin Cardiac Amyloidosis
RECRUITING · NA
-
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
RECRUITING
-
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06754046 · 476 participants · NA
BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)
- NCT03911700 · 477 participants · NA
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
- NCT06997497 · 477 participants · Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- NCT01788839 · 475 participants
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI